Trimeris Overview

  • Founded
  • 1993
  • Status
  • Public
  • Employees
  • 172
  • Stock Symbol
  • TRMS
Stock Symbol
  • Investments
  • 1

Trimeris General Information


Developer of commercial applications of antiviral drug treatments that utilize a class of fusion inhibitors.The company develops novel anti human immunodeficiency virus therapeutics.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Stock Exchange
Primary Office
  • 2530 Meridian Parkway
  • Second Floor
  • Durham, NC 27713
  • United States
+1 (919) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Trimeris Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Trimeris‘s full profile, request access.

Request a free trial

Trimeris Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trimeris Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 03-Nov-2011 0000000 000000 00000 Biotechnology
To view Trimeris’s complete acquisitions history, request access »

Trimeris Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 03-Nov-2011 0000000 000000 00000 Completed
  • 00000000
To view Trimeris’s complete exits history, request access »